Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sirijit Suttajit, Chiang Mai University
ClinicalTrials.gov Identifier:
NCT01590784
First received: April 27, 2012
Last updated: July 27, 2016
Last verified: July 2016
  Purpose

Depression in patients with schizophrenia is common. Several factors was found to be associated with depression including medical illness, quality of life, positive symptoms, and typical antipsychotics. The Calgary depression scale of schizophrenia (CDSS) is commonly used for screening depression in schizophrenia,however; the Thai version of CDSS has not been validated.

This study aims to a.) test the reliability and validity of the Thai version of Calgary depression scale of schizophrenia (CDSS) and b.) identify the prevalence and factors associated with depression in patients with schizophrenia including quality of life, type of antipsychotic drugs, and severity of schizophrenia in 60 patients with schizophrenia at the Faculty of Medicine, Chiang Mai University, Thailand.


Condition
Depression

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: The Reliability and Validity of the Thai Version of Calgary Depression Scale for Schizophrenia (CDSS)

Resource links provided by NLM:


Further study details as provided by Chiang Mai University:

Primary Outcome Measures:
  • The reliability of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The inter-rater reliability, the test-retest reliability will be analyzed.

  • The validity of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Åsberg Depression Rating Scale (MADRS) will be administered by the first rater, whereas the CDSS will be assessed by a second independent rater.


Secondary Outcome Measures:
  • The prevalence of depression in patients with schizophrenia [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The point prevalence of depression in patients with schizophrenia will be presented in percentage.

  • The association between depression in schizophrenia and quality of life. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The association between depression in schizophrenia and quality of life (WHOQOL-BREF-THAI).

  • The association between depression in schizophrenia and type of antipsychotic drugs. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The association between depression in schizophrenia and type of antipsychotic drugs (typical vs atypical).

  • The association between depression in schizophrenia and severity of schizophrenia. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The association between depression in schizophrenia and severity of schizophrenia (PANSS score).


Enrollment: 60
Study Start Date: January 2012
Study Completion Date: November 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Measurements:

The Thai version of Calgary depression scale of schizophrenia (CDSS), Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Asberg Depression Rating Scale (MADRS), the Thai abbreviated version of World Health Organization quality of life (WHOQOL-BREF-THAI).

  Eligibility

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pariticipants diagnosed with schizophrenia according to DSM-IV-TR.
Criteria

Inclusion Criteria:

  • Aged 18 years or over
  • Diagnosis of schizophrenia according to DSM-IV-TR

Exclusion Criteria:

  • Having organic brain syndrome
  • Not fluent in Thai
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01590784

Locations
Thailand
Chiang Mai University
Chiang Mai, Thailand, 50200
Sponsors and Collaborators
Chiang Mai University
Investigators
Study Director: Sirijit Suttajit, MD, MSc Chiang Mai University
  More Information

Responsible Party: Sirijit Suttajit, University instructor, Chiang Mai University
ClinicalTrials.gov Identifier: NCT01590784     History of Changes
Other Study ID Numbers: PSY-11-09-09-12 
Study First Received: April 27, 2012
Last Updated: July 27, 2016
Health Authority: Thailand: Ethical Committee

Keywords provided by Chiang Mai University:
Depression
Schizophrenia

Additional relevant MeSH terms:
Depression
Depressive Disorder
Schizophrenia
Behavioral Symptoms
Mood Disorders
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders

ClinicalTrials.gov processed this record on August 25, 2016